Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. [artículo]
Por: Rivera Díaz, Raquel [Dermatología Médico-Quirúrgica y Venereología]
| Vanaclocha Sebastián, Francisco [Dermatología Médico Quirúrgica y Venereología].
Colaborador(es): Servicio de Dermatología Médico-Quirúrgica y Venereología.
Editor: Archives of Dermatology, 2012Descripción: 148(4):463-70.Recursos en línea: Solicitar documento Resumen: OBJECTIVE: To describe the use of systemic therapy for psoriasis (biologic and nonbiologic [classic] drugs) in patients not adequately represented in randomized controlled trials (RCTs) and the risk of serious adverse events (SAEs) in these patients.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
P1545 (Navegar estantería) | Disponible |
Formato Vancouver:
García-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012 Apr;148(4):463-70.
PMID: 22508869
Contiene 18 referencias
OBJECTIVE: To describe the use of systemic therapy for psoriasis (biologic and nonbiologic [classic] drugs) in patients not adequately represented in randomized controlled trials (RCTs) and the risk of serious adverse events (SAEs) in these patients.
No hay comentarios para este ejemplar.